Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study

被引：1
|
作者：
Zhang, P. [1 ]
Gong, J. [2 ]
Guo, H. [3 ]
Han, W. [4 ]
Cao, B. [5 ]
Zhang, J. [6 ]
Niu, Z. [7 ]
Cheng, Y. [8 ]
He, C. [9 ]
Fan, J. [10 ]
Peng, P. [11 ]
Sun, C. [12 ]
Wang, H. [12 ]
Yu, Y. [12 ]
Zhu, Y. [12 ]
Wu, Y. [12 ]
Li, Q. [12 ]
Huang, P. [12 ]
Wu, F. [11 ]
Shen, L. [13 ]
机构：
[1] Peking Univ, GI Dept, Beijing Canc Hosp, Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Gastrointestinal Oncol, Beijing, Peoples R China
[3] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Sch Med,Urol, Nanjing, Peoples R China
[4] Hunan Canc Hosp, Urol, Changsha, Peoples R China
[5] Peking Univ Third Hosp, Dept Oncol, Beijing, Peoples R China
[6] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Shandong Univ, Dept Gastroenterol, Shandong Canc Hosp, Jinan, Peoples R China
[8] Jilin Canc Hosp, Thorac Oncol Dept, Changchun, Jilin, Peoples R China
[9] Henan Canc Hosp, Urol, Zhengzhou, Peoples R China
[10] TransThera Sci US Inc, Clin Div, Gaithersburg, MD USA
[11] TransThera Sci Nanjing Inc, Nanjing, Peoples R China
[12] TransThera Sci Nanjing Inc, Clin Dept, Nanjing, Peoples R China
[13] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
670P
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [21] Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
    Ida, Hanae
    Shimizu, Toshio
    Nishino, Makoto
    Nakamura, Yoshiaki
    Yazaki, Shu
    Katsuya, Yuki
    Sato, Jun
    Koyama, Takafumi
    Iwasa, Satoru
    Sudo, Kazuki
    Kondo, Shunsuke
    Yonemori, Kan
    Shitara, Kohei
    Shiono, Satoshi
    Matsuoka, Daiko
    Yasuda, Keisuke
    Otake, Yohei
    Suzuki, Takuya
    Takase, Takao
    Takashima, Shuya
    Yamaguchi, Kohei
    Semba, Taro
    Yamamoto, Noboru
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (07): : 1189 - 1199
  • [22] Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
    Chugh, R.
    Kummar, S.
    Schneider, R. E.
    Janik, T.
    Manamley, N.
    Hilgier, K.
    Strauss, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1048 - S1048
  • [23] Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.
    Liu, Chang
    Zhang, Miao
    Yuan, Jiajia
    Liu, Dan
    Gong, Jifang
    Zhu, Yi
    Lin, Lishan
    Sun, Yongkui
    Nippgen, Johannes
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Bao, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [26] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
  • [27] A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
    Goh, Jeffrey
    Gao, Ben
    Markman, Ben
    Gan, Hui
    Voskoboynik, Mark
    Wu, Yi-Long
    Guo, Jun
    Zhou, Qing
    Zhao, Jun
    Chen, Cheng
    Qiu, Jingjun
    Xu, Yingying
    Yang, Liu
    Millward, Michael
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
    Yuan, Peng
    Shentu, Jianzhong
    Xu, Jianming
    Burke, Wendy
    Hsu, Kate
    Learoyd, Maria
    Zhu, Min
    Xu, Binghe
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 963 - 974
  • [29] Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
    Peng Yuan
    Jianzhong Shentu
    Jianming Xu
    Wendy Burke
    Kate Hsu
    Maria Learoyd
    Min Zhu
    Binghe Xu
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 963 - 974
  • [30] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
12345